IMUX

Immunic, Inc.

Healthcare
Biotechnology
$156M market cap

Forecast run · Sep 14, 2026Upside rank 269 of 3,136

Model Signal

ForecastQ Daily Probabilities

63.3%

35.2%

42.2%

Analyst Consensus

Recommendation2.17/5 Buy

Last price$11.42

Price target$22.13

Implied move+93.8%

Analysts12

ForecastQ Portfolios

IMUX is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.